Expanded Access Study of Atezolizumab for Advanced or Metastatic Urothelial Cancer After Platinum Chemotherapy Failure

Inclusion Criteria

• Must be able to follow the study requirements.
• Have advanced or metastatic urothelial cancer confirmed by lab tests.
• Cancer must have worsened during or after treatment with at least one platinum-based chemotherapy regimen, such as gemcitabine and cisplatin.
• Have a performance status score of 0, 1, or 2, indicating full activity or some restriction in strenuous activities.
• Expected to live at least 12 more weeks.
• Have adequate blood and organ function based on recent lab tests.
• Women who can become pregnant must agree to use effective non-hormonal birth control during the study and for 90 days after the last dose.

Exclusion Criteria

• Have participated in another clinical trial or received an investigational drug within 28 days before joining this study.
• Have received chemotherapy within 14 days before joining the study.
• Have received radiotherapy within 7 days before joining the study.
• Have cancer that has spread to the brain or have symptoms from such spread.
• Are pregnant, breastfeeding, or planning to become pregnant during the study.
• Have significant heart disease or recent heart attack.
• Have had severe infections or been hospitalized for infections within 4 weeks before joining the study.
• Have taken antibiotics by mouth or IV within 14 days before joining the study.
• Have had major surgery within 4 weeks before joining the study.
• Have severe allergies to similar drugs or components of atezolizumab.
• Have active hepatitis B or tuberculosis.
• Have received a live vaccine within 4 weeks before joining the study.
• Have taken drugs that stimulate the immune system or suppress it within a certain time before joining the study.